ITM Isotopen Technologien München AG
ITM AG: A new approach to Safety and Convenience in
Radiopharmacy and Brachytherapy !
After careful analysis and consideration of the current challenges and future requirements in nuclear medicine and radiopharmacy, Isotope Technologies Munich AG (ITM AG) was founded at the site of the new Neutron Source FRM-II in Garching with the mission:
“To boost growth and profitability in the radiopharmaceutical industry by providing safe, standardized and integrated solutions to the key market participants through integrated supply-chain technologies, products and services.”
In this context an integrated radiopharmaceutical processing, quality assurance and safety system - the iQS-System - has been developed and patents filed. The proprietary iQS-System enables the safe and efficient handling and processing of a wide range of radio-isotopes in combination with different pharmacological targeting substances and performs the final production and Quality Assurance steps of radio therapeutics and -diagnostics at the point of care in the hospitals.
In the framework of multiple development and production programs and dedicated studies conducted, among others, with the Federal Radiation Protection Agency (BfS, Bundesamt für Strahlenschutz), the assumptions and positive effects of this approach to radiation safety and convenience in the clinical application of targeted radiotherpies could be verified and validated.